The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
CalvertA.H., NewellD.R., GumbrellL.A.Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol.1989; 7: 1748–56.
2.
CalvertA.H., HarlandS.J., NewellD.R.Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev.1985; 12(suppl A): 51–7.
3.
MillwardM.J., WebsterL.K., TonerG.C.Carboplatin dosing based on measurement of renal function: Experience at the Peter MacCallum Cancer Institute. Aust NZ J Med.1996; 26: 372–9.
4.
RahnK.H., HeidenreichS., BrucknerD.How to assess glomerular function and damage in humans. J Hypertens.1999; 17: 309–17.
5.
DaugaardG., RossingN., RorthM.Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol.1988; 21: 163–7.
6.
RobinsonB.A., FramptonC.M., CollsB.M.Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin, or methotrexate. Aust NZ J Med.1990; 20: 657–62.
7.
CockcroftD.W., GaultM.H.Prediction of creatinine clearance from serum creatinine. Nephron.1976; 16: 31–41.
8.
OkamotoH., NagatomoA., KunitohH.Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol.1998; 42: 307–12.
9.
ChoyH., AkerleyW., SafranH.Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol.1998; 16: 3316–22.
10.
LampeH., DearnaleyD P., PriceA.High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumors. Eur J Cancer.1995; 31A: 717–23.
11.
Du BoisD., Du BoisE.F.A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med.1916; 17: 863–71.
12.
KellyK., CrowleyJ., BunnP.A.A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial. Proc Am Soc Clin Oncol.1999; 18: 461a.
13.
BertinoJ.S.Measured versus estimated creatinine clearance in patients with low serum creatinine values. Ann Pharmacother.1993; 27: 1439–42.
14.
SmytheM., HoffmanJ., KizyK.Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm.1994; 51: 198–204.
15.
MinamH., AndoY., AndoM.Overdosing of carboplatin (CBDCA) by creatinine clearance (Ccr)-based dosing and its adjustment. Proc Am Soc Clin Oncol.1997; 16: 204a.
16.
DionneR.E., BauerL.A., GibsonG.A.Estimating creatinine clearance in morbidly obese patients. Am J Hosp Pharm.1981; 38: 841–4.
17.
HailemeskelB.Creatinine clearance estimation in obese patients using Cockcroft and Gault equation with ideal, actual, adjusted, or no body weight. ASHP Midyear Clinical Meeting.1998; 33(Dec): P-CR22.
18.
HutsonP.R., TutschK.D., PomplunM.Carboplatin dosing in obese patients. Proc Am Soc Clin Oncol.2000; 19: 187a.
19.
TuckerG.R., AlexanderJ.K.Estimation of body surface area in extremely obese subjects. J Appl Physiol.1960; 15: 781–4.
20.
WaddellJ.A., HannanL.C., EchevarriaK.L.Detection of prescribing errors in Calvert formula dosing of carboplatin [abstract]. J Am Pharm Assoc.1999; 39: 246.
21.
SolimandoD.A., WaddellJ.A.A comparison of antineoplastic medication errors detected by oncology pharmacists at two teaching medical centers [abstract]. J Oncol Pharm Pract.1998; 4: 52.
